2019
DOI: 10.1002/path.5283
|View full text |Cite
|
Sign up to set email alerts
|

Intraductal carcinoma of the prostate in the absence of high‐grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations

Abstract: Intraductal carcinoma of the prostate (IDC‐P) most often appears associated with high‐grade invasive prostate carcinoma (PCa), where it is believed to represent retrograde spread. However, IDC‐P rarely occurs as an isolated finding at radical prostatectomy or with concurrent low‐grade (Grade Group 1) invasive carcinoma. We hypothesized that isolated IDC‐P (iIDC‐P) in these unusual cases may represent a distinct in situ lesion and molecularly profiled 15 cases. iIDC‐P was characterized by copy number alteration… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
61
1

Year Published

2020
2020
2024
2024

Publication Types

Select...
5
1
1

Relationship

0
7

Authors

Journals

citations
Cited by 51 publications
(63 citation statements)
references
References 56 publications
1
61
1
Order By: Relevance
“…Although IDC-P is relatively rare type among prostate cancer, frequency of IDCP increases after androgen deprivation therapy and presence of IDC-P is associated with higher risk of cancer progression [8]. Genomic feature of IDC-P is higher percentage of genomic alteration including PTEN, RB1, TP53 and CHEK2 [9,10]. However, Asian cases of IDC-P with CHEK2 mutations have not been reported previously.…”
Section: Discussionmentioning
confidence: 99%
“…Although IDC-P is relatively rare type among prostate cancer, frequency of IDCP increases after androgen deprivation therapy and presence of IDC-P is associated with higher risk of cancer progression [8]. Genomic feature of IDC-P is higher percentage of genomic alteration including PTEN, RB1, TP53 and CHEK2 [9,10]. However, Asian cases of IDC-P with CHEK2 mutations have not been reported previously.…”
Section: Discussionmentioning
confidence: 99%
“…[31][32][33][34] Similarly to invasive carcinoma, approximately 50% of IDCp show expression of ERG and 60% show loss of PTEN. 11,31 Of note our case of isolated IDCp was negative for ERG staining. In addition, even the lesions that do not fit in the strict morphological criteria for IDCp may be associated with invasive carcinomas or IDCp in the repeat biopsy.…”
Section: Discussionmentioning
confidence: 65%
“…43 Recently, Khani et al studied 15 cases of IDCp with concurrent low-grade invasive carcinoma (Gleason score 6/Prognostic Grade Group 1) in radical prostatectomies. 11 They analyzed the molecular profile of these cases with next-generation sequencing and performed immunohistochemistry for PTEN and ERG. Interestingly, 4 of the 15 cases had activated the MAPK/PI3K signaling pathway in the IDCp component, a pathway not usually associated with prostate adenocarcinoma.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations